MYGN Form 4 exit: EVP Strategy & Transformation position ends
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Myriad Genetics (MYGN) filed a Form 4/Exit noting a leadership change. The filing states that, effective on November 3, 2025, the reporting person no longer serves as EVP, Strategy & Transformation and therefore is no longer subject to Section 16 reporting.
The report lists 127,726 shares of common stock beneficially owned directly following the reported event. The form was filed by one reporting person.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ancona Margaret
Role
EVP, Strategy & Transformation
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 127,726 shares (Direct)
Footnotes (1)
FAQ
What did MYGN disclose in this Form 4/Exit filing?
It reports that the officer no longer serves as EVP, Strategy & Transformation as of November 3, 2025, and is no longer subject to Section 16 reporting.
When did the MYGN EVP Strategy & Transformation role end?
The role ended effective November 3, 2025.
Does this MYGN filing involve multiple reporting persons?
No. It indicates the form was filed by one reporting person.
What is the officer’s relationship to MYGN noted in the filing?
The reporting person was an Officer, titled EVP, Strategy & Transformation.
What is the stated effect on Section 16 status for the reporting person?
They are no longer subject to Section 16 reporting as of the effective date.